MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6604-864-869$20.00
Mol Pharmacol 66:864-869, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rao, B. M.
Right arrow Articles by Wittrup, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rao, B. M.
Right arrow Articles by Wittrup, K. D.

Interleukin 2 (IL-2) Variants Engineered for Increased IL-2 Receptor {alpha}-Subunit Affinity Exhibit Increased Potency Arising from a Cell Surface Ligand Reservoir Effect

Balaji M. Rao, Ian Driver, Douglas A. Lauffenburger, and K. Dane Wittrup

Department of Chemical Engineering (B.M.R., I.D.) and Biological Engineering Division (D.A.L., K.D.W.), Massachusetts Institute of Technology, Cambridge, Massachusetts

Proliferation of activated T cells and CD56 bright natural killer ( Cytokine Growth Factor Rev 13:169-183, 1995) cells caused by interleukin-2 (IL-2) has been exploited in IL-2-based therapies for the treatment of metastatic renal cell carcinoma and melanoma ( J Clin Oncol 13:688-696, 1995; J Clin Oncol 17: 2105-2116, 1999). In this study, we demonstrate the potentially improved therapeutic value of IL-2 variants engineered to gain 15- to 30-fold increased affinity for the IL-2 receptor {alpha}-subunit (IL-2R{alpha}). A novel pulsed bioassay was used to more closely approximate the rapid systemic clearance pharmacokinetics of cytokines such as IL-2, compared with conventional static bioassays. In this assay, mutants with increased affinity for IL-2R{alpha} exhibit significantly increased activity for T-cell proliferation, whereas static bioassays not only fail to reveal the increased activity resulting from enhanced IL-2R{alpha} affinity (false negatives), but also suggest improved activity for another mutant without enhanced activity in the pulsed assay (false positive). Our studies on the mechanism leading to increased activity of IL-2 mutants with increased IL-2R{alpha} affinity suggest that cell-surface IL-2R{alpha} acts as a ligand reservoir for the IL-2 mutants. This leads to increased cell-surface persistence of the IL-2 mutants with increased IL-2R{alpha} affinity in cell-surface ligand reservoirs and consequently increased integrated growth signal. Furthermore, a mathematical model predicts increased persistence of cell surface-bound IL-2 in vivo for enhanced IL-2R{alpha}-binding IL-2 mutants, suggesting potentially improved therapeutic value of allowing cellular capture of ligands in persistent cell-surface reservoirs. Finally, our findings emphasize the critical choice of appropriate bioassays to evaluate engineered proteins and other drugs.


Received February 26, 2004; accepted July 14, 2004

Address correspondence to: K. Dane Wittrup, MIT 66-552, Cambridge, MA 02139. E-mail: wittrup{at}mit.edu




This article has been cited by other articles:


Home page
Protein Eng Des SelHome page
J. R. Cochran, Y.-S. Kim, S. M. Lippow, B. Rao, and K.D. Wittrup
Improved mutants from directed evolution are biased to orthologous substitutions
Protein Eng. Des. Sel., June 1, 2006; 19(6): 245 - 253.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics